Telix Pharmaceuticals Limited ADR (TLX)
NASDAQ: TLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TLX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.78B
- P/E (TTM)
- 111.20
- EPS (TTM)
- $0.10
- Dividend yield
- None
- 52-week range
- 6.28 – 13.11
- Day range
- 11.01 – 11.14
- Volume / Avg
- 817.43K / 248.69K
- Beta
- —
- Shares outstanding
- 339.78M
52-week range
TLX stock today
Telix Pharmaceuticals (TLX) closed at $11.12 on Oct 7, up 3.15% (+$0.34), versus the S&P 500's 0.22% decline. Volume was 3.3x the average at 817.43K shares, a sign of unusually heavy trading. At this level, TLX sits in the middle of its 52-week range of $6.28 to $13.11: 15.2% below the high, set on Sep 15, 2026 and 77.1% above the low.
TLX is up 48.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 11.8%. Telix Pharmaceuticals trades at 111.2x its trailing twelve-month earnings per share of $0.10.
Summary generated from market data by MetaCap's automated system. Methodology
About Telix Pharmaceuticals
Company profileTelix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
- Headquarters
- North Melbourne, VIC
- Employees
- 1,120
- Website
- telixpharma.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$20.42+83.63%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Telix Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs TLX |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs TLX |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs TLX |
| OGNOrganon & Co. | 13.79 | +0.36% | $3.62B | vs TLX |
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs TLX |
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs TLX |
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs TLX |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs TLX |
Indexes, lists and sector
Telix Pharmaceuticals stock FAQ
What is Telix Pharmaceuticals's stock price today?
TLX last traded at $11.12 as of Oct 7, 4:00 PM EDT, up 3.15% on the day. Prices are delayed at least 15 minutes.
What is TLX's P/E ratio?
TLX trades at a trailing P/E ratio of 111.20.
Who is Telix Pharmaceuticals's CEO?
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D is the chief executive officer of Telix Pharmaceuticals Limited ADR, which has about 1,120 employees.
What is the TLX 52-week high?
The 52-week high for TLX is $13.11 and the 52-week low is $6.28. The stock is currently 15.2% below its high.